Company / Net Income
Myriad Genetics, Inc. Net Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
-$365.9M
FY2025
5-year range
-$365.9M / -$27.2M
FY2021-FY2025
Trend
-187.4%
vs FY2024
Sector context
#189 of 216
Health Care
What the data says
Myriad Genetics, Inc.'s net income of -$366M is lower than 87% of companies in the Health Care sector (FY2025). Net Income has fluctuated over the past 10 years, ranging from -$366M in FY2025 to $133M in FY2018.
Based on SEC 10-K filings.
-$366M in FY2025.
Declined from -$263M to -$366M over the past 2 years.
Health Care sector context is included.
Net Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 13% in Health CareTop 87% of 216This company -$365.9M Sector average $454.1M
▼
-180.6% below sector average
Key checks
Key Insights
- In FY2025, net income decreased 187.4% year-over-year.
- Ranks #189 out of 216 companies in the Health Care sector.
- Peak net income was recorded in FY2018.
Company context
Key Data Points
- Altman Z-Score -1.23 (distress zone, below 1.8 threshold)
- Negative profit margin: -15.2%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$365.9M | -187.4% |
| FY2024 | -$127.3M | +51.7% |
| FY2023 | -$263.3M | -135.1% |
| FY2022 | -$112.0M | -311.8% |
| FY2021 | -$27.2M | +86.4% |
| FY2020 | -$199.5M | -1246.6% |
| FY2019 | $17.4M | -86.9% |
| FY2018 | $133.3M | +666.1% |
| FY2017 | $17.4M | -85.2% |
| FY2016 | $117.2M | +46.9% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026